Cargando…

Continuation of therapeutic dose heparin for critically ill patients with COVID-19

Detalles Bibliográficos
Autores principales:	Bradbury, Charlotte A., Lawler, Patrick R., McVerry, Bryan J., Zarychanski, Ryan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231279/ https://www.ncbi.nlm.nih.gov/pubmed/37256341 http://dx.doi.org/10.1007/s00134-023-07095-8

Ejemplares similares

Effect of therapeutic-dose heparin on severe acute kidney injury and death in noncritically ill patients hospitalized for COVID-19: a prespecified secondary analysis of the ACTIV4a and ATTACC randomized trial
por: Smilowitz, Nathaniel R., et al.
Publicado: (2023)

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
Publicado: (2021)

CRITICALLY ILL COVID-19 PATIENTS AND THERAPEUTIC ANTICOAGULATION WITH HEPARIN
por: Vu, Michael, et al.
Publicado: (2022)

Optimal doses of caspofungin during continuous venovenous hemodiafiltration in critically ill patients
por: Aguilar, Gerardo, et al.
Publicado: (2017)

Rectal Swabs from Critically Ill Patients Provide Discordant Representations of the Gut Microbiome Compared to Stool Samples
por: Fair, Katherine, et al.
Publicado: (2019)

Cefepime-induced neurotoxicity in critically ill patients undergoing continuous renal replacement therapy: beware of dose reduction!
por: Honore, Patrick M., et al.
Publicado: (2015)

Treatment of influenza virus-related critical illness during continuous renal replacement therapy: take caution with dosing
por: Honore, Patrick M., et al.
Publicado: (2020)

Dosing adjuvant vitamin C in critically ill patients undergoing continuous renal replacement therapy: We are not there yet!
por: Honore, Patrick M., et al.
Publicado: (2019)

Plasma microbial cell-free DNA load is associated with mortality in patients with COVID-19
por: Kitsios, Georgios D., et al.
Publicado: (2021)

The blind spot in high-dose tigecycline pharmacokinetics in critically ill patients: membrane adsorption during continuous extracorporeal treatment
por: Honore, Patrick M, et al.
Publicado: (2015)

Argatroban for therapeutic anticoagulation for heparin resistance associated with Covid-19 infection
por: McGlynn, Fergal, et al.
Publicado: (2020)

Use of insulin and heparin in the management of severe hypertriglyceridemia in a critically ill patient
por: Arranz, Natàlia, et al.
Publicado: (2022)

Type and dose of heparin in Covid‐19: Reply
por: Thachil, Jecko, et al.
Publicado: (2020)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Beta-lactam antibiotics in continuous infusion in critically ill patients
por: Jeurissen, Axel, et al.
Publicado: (2010)

Continuous infusion of meropenem in critically ill patients: practical considerations
por: Taccone, Fabio Silvio
Publicado: (2012)

Continuous capnography monitoring during transport of critically ill patients
por: Venkatesan, Kumaresh
Publicado: (2016)

Biomarker validity in the critically ill: all must face the (continuous) renal replacement challenge!
por: Honore, Patrick M., et al.
Publicado: (2015)

Comparison of three cisatracurium dosing strategies in acute respiratory distress syndrome: A focus on drug utilization and improvement in oxygenation
por: DiBridge, Julie N., et al.
Publicado: (2021)

Heparin algorithm for anticoagulation during continuous renal replacement therapy
por: Ostermann, Marlies, et al.
Publicado: (2010)

Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19
por: Neal, Matthew D., et al.
Publicado: (2022)

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
Publicado: (2021)

Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies?
por: Honore, Patrick M., et al.
Publicado: (2018)

Revised algorithm for heparin anticoagulation during continuous renal replacement therapy
por: Dickie, Helen, et al.
Publicado: (2015)

A common single nucleotide polymorphism is associated with inflammation and critical illness outcomes
por: El-Dehaibi, Fayten, et al.
Publicado: (2023)

Colistin dosing for treatment of multidrug-resistant Pseudomonas in critically ill patients - please, be adequate!
por: Honoré, Patrick M, et al.
Publicado: (2014)

Regional Anticoagulation with Citrate is Superior to Systemic Anticoagulation with Heparin in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration
por: Park, Joon-Sung, et al.
Publicado: (2011)

Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration
por: Aguilar, Gerardo, et al.
Publicado: (2019)

Distinct profiles of host responses between plasma and lower respiratory tract during acute respiratory failure
por: Kitsios, Georgios D., et al.
Publicado: (2023)

Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
por: Gurjar, Mohan
Publicado: (2014)

The Impact of COVID-19 Research on the Development of Scalable Frameworks for Efficient Clinical Trials in Cardiovascular Medicine
por: Godoy, Lucas C., et al.
Publicado: (2023)

Is protein intake saturated at doses recommended by the feeding guidelines for critically ill patients?
por: Gunst, Jan, et al.
Publicado: (2018)

Plasma SARS-CoV-2 RNA levels as a biomarker of lower respiratory tract SARS-CoV-2 infection in critically ill patients with COVID-19
por: Jacobs, Jana L., et al.
Publicado: (2022)

Pharmacokinetics and the optimal regimen for levofloxacin in critically ill patients receiving continuous hemodiafiltration
por: Wada, Takeshi, et al.
Publicado: (2015)

A low dose heparinized saline protocol is associated with improved duration of arterial line patency in critically ill COVID-19 patients
por: Maurer, Lydia R., et al.
Publicado: (2020)

Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study
por: Al Sulaiman, Khalid, et al.
Publicado: (2022)

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
por: Arabi, Yaseen M., et al.
Publicado: (2021)

Measuring the anticoagulant effect of low molecular weight heparins in the critically ill
por: Crowther, Mark, et al.
Publicado: (2006)

Incidence and clinical relevance of heparin-induced antibodies in critically ill patients
por: Grigoriou, P, et al.
Publicado: (2004)

Therapeutic Drug Monitoring of Isavuconazole—But What about the Critically Ill?
por: Salhotra, Ripenmeet
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qm472ttnb0kn9srnqr54tmqsrf